2014 Q1 Form 10-Q Financial Statement
#000110465914038146 Filed on May 13, 2014
Income Statement
Concept | 2014 Q1 | 2013 Q4 | 2013 Q1 |
---|---|---|---|
Revenue | $9.081M | $10.33M | $147.0K |
YoY Change | 6077.55% | 848.07% | -29.33% |
Cost Of Revenue | $494.0K | $1.100M | $0.00 |
YoY Change | |||
Gross Profit | $8.587M | $9.300M | $100.0K |
YoY Change | 8487.0% | ||
Gross Profit Margin | 94.56% | 89.99% | 68.03% |
Selling, General & Admin | $17.53M | $15.20M | $13.53M |
YoY Change | 29.51% | 74.71% | 396.08% |
% of Gross Profit | 204.11% | 163.44% | 13533.0% |
Research & Development | $4.482M | $5.400M | $4.522M |
YoY Change | -0.88% | 3.85% | -15.6% |
% of Gross Profit | 52.2% | 58.06% | 4522.0% |
Depreciation & Amortization | $227.0K | $200.0K | $162.0K |
YoY Change | 40.12% | 0.0% | -28.0% |
% of Gross Profit | 2.64% | 2.15% | 162.0% |
Operating Expenses | $22.01M | $20.60M | $18.06M |
YoY Change | 21.9% | 49.28% | 123.29% |
Operating Profit | -$13.42M | -$11.30M | -$17.91M |
YoY Change | -25.05% | 127.32% | |
Interest Expense | $1.207M | -$2.700M | $727.0K |
YoY Change | 66.02% | 237.5% | -24.43% |
% of Operating Profit | |||
Other Income/Expense, Net | -$2.121M | $0.00 | -$506.0K |
YoY Change | 319.17% | -63.83% | |
Pretax Income | -$15.50M | -$22.40M | -$18.40M |
YoY Change | -15.76% | 65.93% | 97.85% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$15.54M | -$22.41M | -$18.41M |
YoY Change | -15.59% | 65.82% | 98.49% |
Net Earnings / Revenue | -171.16% | -216.82% | -12526.53% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$370.8K | -$645.5K | -$595.5K |
COMMON SHARES | |||
Basic Shares Outstanding | 42.04M shares | 30.89M shares | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2014 Q1 | 2013 Q4 | 2013 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $58.90M | $82.20M | $69.90M |
YoY Change | -15.74% | -7.12% | 86.9% |
Cash & Equivalents | $12.25M | $32.98M | $18.91M |
Short-Term Investments | $46.60M | $49.20M | $51.00M |
Other Short-Term Assets | $2.800M | $2.800M | $1.000M |
YoY Change | 180.0% | 154.55% | 0.0% |
Inventory | $7.957M | $7.152M | $3.113M |
Prepaid Expenses | |||
Receivables | $9.725M | $5.054M | $1.650M |
Other Receivables | $700.0K | $0.00 | $600.0K |
Total Short-Term Assets | $79.93M | $97.16M | $76.33M |
YoY Change | 4.71% | 6.23% | 98.69% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $2.648M | $2.554M | $1.687M |
YoY Change | 56.97% | 79.73% | 40.58% |
Goodwill | |||
YoY Change | |||
Intangibles | $2.157M | $1.158M | $626.0K |
YoY Change | 244.57% | 69.55% | |
Long-Term Investments | $11.70M | $8.800M | |
YoY Change | |||
Other Assets | $360.0K | $361.0K | $363.0K |
YoY Change | -0.83% | 8.08% | -86.56% |
Total Long-Term Assets | $17.59M | $13.83M | $2.729M |
YoY Change | 544.6% | 447.45% | -42.97% |
TOTAL ASSETS | |||
Total Short-Term Assets | $79.93M | $97.16M | $76.33M |
Total Long-Term Assets | $17.59M | $13.83M | $2.729M |
Total Assets | $97.52M | $111.0M | $79.06M |
YoY Change | 23.35% | 18.09% | 83.0% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $2.200M | $3.100M | $3.700M |
YoY Change | -40.54% | -61.25% | -60.22% |
Accrued Expenses | $12.49M | $15.17M | $7.240M |
YoY Change | 72.51% | 93.03% | 503.33% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $12.10M | ||
YoY Change | 31.52% | ||
Total Short-Term Liabilities | $27.10M | $26.40M | $27.01M |
YoY Change | 0.35% | 14.87% | 35.64% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $28.40M | $34.40M | $8.000M |
YoY Change | 255.0% | 209.91% | -59.8% |
Other Long-Term Liabilities | $2.101M | $2.677M | $1.860M |
YoY Change | 12.96% | 49.72% | -40.0% |
Total Long-Term Liabilities | $2.101M | $2.677M | $1.860M |
YoY Change | 12.96% | 49.72% | -91.91% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $27.10M | $26.40M | $27.01M |
Total Long-Term Liabilities | $2.101M | $2.677M | $1.860M |
Total Liabilities | $68.51M | $77.53M | $37.79M |
YoY Change | 81.29% | 112.89% | -11.97% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$194.1M | -$178.5M | -$104.7M |
YoY Change | 85.41% | 106.98% | |
Common Stock | $42.00K | $40.00K | $31.00K |
YoY Change | 35.48% | 29.03% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $29.01M | $33.46M | $41.27M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $97.52M | $111.0M | $79.06M |
YoY Change | 23.35% | 18.09% | 83.0% |
Cashflow Statement
Concept | 2014 Q1 | 2013 Q4 | 2013 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$15.54M | -$22.41M | -$18.41M |
YoY Change | -15.59% | 65.82% | 98.49% |
Depreciation, Depletion And Amortization | $227.0K | $200.0K | $162.0K |
YoY Change | 40.12% | 0.0% | -28.0% |
Cash From Operating Activities | -$19.10M | -$9.400M | -$17.22M |
YoY Change | 10.92% | -41.61% | 71.07% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $263.0K | -$200.0K | $372.0K |
YoY Change | -29.3% | 0.0% | 830.0% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$1.400M | $21.10M | -$2.800M |
YoY Change | -50.0% | -331.87% | -86.98% |
Cash From Investing Activities | -$1.629M | $20.90M | -$3.149M |
YoY Change | -48.27% | -322.34% | -85.39% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $6.000K | $1.936M | |
YoY Change | -99.69% | 3851.02% | |
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $5.000K | -1.500M | -$1.021M |
YoY Change | -100.49% | -103.54% | -3.41% |
NET CHANGE | |||
Cash From Operating Activities | -$19.10M | -9.400M | -$17.22M |
Cash From Investing Activities | -$1.629M | 20.90M | -$3.149M |
Cash From Financing Activities | $5.000K | -1.500M | -$1.021M |
Net Change In Cash | -$20.73M | 10.00M | -$21.39M |
YoY Change | -3.11% | -40.83% | -34.53% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$19.10M | -$9.400M | -$17.22M |
Capital Expenditures | $263.0K | -$200.0K | $372.0K |
Free Cash Flow | -$19.37M | -$9.200M | -$17.60M |
YoY Change | 10.07% | -42.14% | 74.07% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2554000 | USD |
CY2013Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | USD |
CY2014Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2648000 | USD |
CY2014Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | USD |
CY2014Q1 | us-gaap |
Depreciation
Depreciation
|
169000 | USD |
CY2013Q1 | us-gaap |
Depreciation
Depreciation
|
106000 | USD |
CY2014Q1 | supn |
Number Of Proprietary Products In Clinical Development
NumberOfProprietaryProductsInClinicalDevelopment
|
2 | product |
CY2014Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
CY2014Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
CY2014Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2676000 | USD |
CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
8145000 | USD |
CY2014Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
8408000 | USD |
CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5591000 | USD |
CY2014Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5760000 | USD |
CY2014Q1 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.0750 | pure |
CY2014Q1 | us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Revenue Recognition on Product Sales</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue from product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, “sales deductions”) as well as estimated product returns.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Our products are distributed through wholesalers and pharmaceutical distributors. Each of these wholesalers and distributors will take title and ownership of the product upon physical receipt of the product and then distribute our products to pharmacies. Though these distributors will be invoiced concurrent with product shipment, we are unable to recognize revenue upon shipment until such time as we can reasonably estimate and record provisions for sales deductions and product returns utilizing historical information and market research projections.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Oxtellar XR Revenue</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company launched Oxtellar XR on February 4, 2013.   During the fourth quarter of 2013, the Company began to recognize revenue for Oxtellar XR contemporaneously upon shipment of finished product to wholesalers, net of allowances for estimated sales deductions and returns.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Trokendi XR Revenue</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company launched Trokendi XR on August 26, 2013.  Through March 31, 2014 the Company recorded shipments to wholesalers as deferred revenue equal to the gross sales price net of known sales deductions. Because we lack the experiential data which would allow us to estimate all remaining sales rebates, allowances and returns,  we must wait until these data become available to the Company in order to recognize revenue upon shipment to wholesalers.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Rather than recognize revenue upon shipments to wholesalers, the Company currently recognizes Trokendi XR revenue upon filling prescriptions at pharmacies because prescriptions filled at the pharmacy level have no remaining right of return.  However, because we are still compiling historical data related to our experience with respect to other sales deductions, we cannot reasonably estimate all other sales rebates and allowances, but rather must wait until this data becomes available to the Company.  Because this occurs approximately eight weeks after the close of the quarter, the Company currently delays recognition of revenue until the subsequent fiscal quarter when all the sales deductions are known.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">With respect to prescriptions which were filled in the fourth quarter, data on rebates and allowances were generally received by the end of the first quarter of 2014. Because of this time lag, the Company could not determine net revenue in a timeframe which would allow reporting fourth quarter net revenue in the Form 10-K filed for the year ended December 31, 2013. Consequently, revenue generated from prescriptions for Trokendi XR filled at the pharmacy level in the fourth quarter are reported in the Company’s first quarter 2014 financial results. We expect to continue to report revenue based on prescriptions filled at the pharmacy level until sufficient experience with rebates and allowances is assembled to allow reporting of revenue based on shipments to wholesalers.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company believes the compilation of sufficient product specific historical data to reasonably estimate returns, rebates, and allowances for Trokendi XR may be available by the second quarter of 2014, at which time the Company may record revenue based on shipments to wholesalers, rather than on prescriptions filled at the pharmacy level.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 3pt; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Milestone Payments</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Milestone payments on licensing agreements are recognized as revenue when the collaborative partner acknowledges completion of the milestone and substantive effort was necessary to achieve the milestone. Management may recognize revenue contingent upon the achievement of a milestone in its entirety in the period in which the milestone is achieved only if the milestone meets all the criteria to be considered substantive.  The Company recorded no milestone revenue during the three months ended March 31, 2014 and 2013.</font></p></div> | |
CY2014Q1 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
76000000 | USD |
CY2013Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
57967000 | USD |
CY2014Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
58276000 | USD |
CY2013Q4 | supn |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
-33000 | USD |
CY2014Q1 | supn |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
-34000 | USD |
CY2013Q4 | supn |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
-33000 | USD |
CY2014Q1 | supn |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
-33000 | USD |
CY2013Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
57967000 | USD |
CY2014Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
58277000 | USD |
CY2013Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
3897000 | USD |
CY2014Q1 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
4188000 | USD |
CY2013Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1347000 | USD |
CY2013Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1908000 | USD |
CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
7152000 | USD |
CY2014Q1 | us-gaap |
Inventory Net
InventoryNet
|
7957000 | USD |
CY2014Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1093000 | USD |
CY2014Q1 | supn |
Number Of Patents Issued
NumberOfPatentsIssued
|
3 | patent |
CY2013Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
57000 | USD |
CY2014Q1 | supn |
Finite Lived Intangible Assets Estimated Annual Aggregate Amortization Expense
FiniteLivedIntangibleAssetsEstimatedAnnualAggregateAmortizationExpense
|
229000 | USD |
CY2013Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
1158000 | USD |
CY2014Q1 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
9565000 | USD |
CY2014Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
57000 | USD |
CY2013Q4 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
2253000 | USD |
CY2014Q1 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
538000 | USD |
CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5016000 | USD |
CY2014Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3829000 | USD |
CY2013Q4 | supn |
Accrued Rebates And Allowances Current
AccruedRebatesAndAllowancesCurrent
|
1903000 | USD |
CY2013Q4 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
2503000 | USD |
CY2013Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1077000 | USD |
CY2014Q1 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1540000 | USD |
CY2013Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
619000 | USD |
CY2014Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
1251000 | USD |
CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1801000 | USD |
CY2014Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1998000 | USD |
CY2013Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
15172000 | USD |
CY2014Q1 | supn |
Deferred Product Revenue Net Current
DeferredProductRevenueNetCurrent
|
12271000 | USD |
CY2014Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12490000 | USD |
CY2014Q1 | supn |
Accrued Rebates And Allowances Current
AccruedRebatesAndAllowancesCurrent
|
2817000 | USD |
CY2014Q1 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
517000 | USD |
CY2013Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
8756000 | USD |
CY2014Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2157000 | USD |
CY2014Q1 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
11662000 | USD |
CY2014Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
360000 | USD |
CY2014Q1 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
764000 | USD |
CY2014Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
14658000 | USD |
CY2014Q1 | supn |
Deferred Revenue Licensing Current
DeferredRevenueLicensingCurrent
|
173000 | USD |
CY2014Q1 | supn |
Deferred Revenue Licensing Noncurrent
DeferredRevenueLicensingNoncurrent
|
1381000 | USD |
CY2014Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2101000 | USD |
CY2014Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
42000 | USD |
CY2014Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
223041000 | USD |
CY2014Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-194071000 | USD |
CY2014Q1 | us-gaap |
Licenses Revenue
LicensesRevenue
|
86000 | USD |
CY2014Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4482000 | USD |
CY2014Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
17527000 | USD |
CY2014Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
102000 | USD |
CY2014Q1 | us-gaap |
Interest Expense
InterestExpense
|
1207000 | USD |
CY2014Q1 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
677000 | USD |
CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.38 | |
CY2014Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
41129055 | shares |
CY2014Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1000 | USD |
CY2014Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
677000 | USD |
CY2014Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
-1000 | USD |
CY2014Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
227000 | USD |
CY2014Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
574000 | USD |
CY2014Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
667000 | USD |
CY2014Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4671000 | USD |
CY2014Q1 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
28358000 | USD |
CY2013Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
337000 | USD |
CY2014Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
667000 | USD |
CY2014Q1 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
153000 | USD |
CY2014Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
805000 | USD |
CY2014Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS INC | |
CY2014Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | |
CY2014Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2014Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-03-31 | |
CY2014Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2014Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2014Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
42046458 | shares |
CY2014Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12252000 | USD |
CY2014Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2014Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
CY2014Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
CY2014Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2013Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
49211000 | USD |
CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5054000 | USD |
CY2013Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
483000 | USD |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2052000 | USD |
CY2013Q4 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
229000 | USD |
CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
97161000 | USD |
CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
361000 | USD |
CY2013Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
1005000 | USD |
CY2013Q4 | us-gaap |
Assets
Assets
|
110995000 | USD |
CY2014Q1 | us-gaap |
Assets Current
AssetsCurrent
|
79929000 | USD |
CY2014Q1 | us-gaap |
Assets
Assets
|
97520000 | USD |
CY2013Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
18314000 | USD |
CY2013Q4 | supn |
Deferred Product Revenue Net Current
DeferredProductRevenueNetCurrent
|
7882000 | USD |
CY2013Q4 | supn |
Deferred Revenue Licensing Current
DeferredRevenueLicensingCurrent
|
204000 | USD |
CY2014Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
1000 | USD |
CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
26400000 | USD |
CY2013Q4 | supn |
Deferred Revenue Licensing Noncurrent
DeferredRevenueLicensingNoncurrent
|
1417000 | USD |
CY2013Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
34393000 | USD |
CY2014Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
507000 | USD |
CY2013Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2677000 | USD |
CY2013Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
12644000 | USD |
CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
77531000 | USD |
CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
40000 | USD |
CY2013Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
211952000 | USD |
CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-178528000 | USD |
CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
33464000 | USD |
CY2014Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
27102000 | USD |
CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
110995000 | USD |
CY2014Q1 | us-gaap |
Liabilities
Liabilities
|
68507000 | USD |
CY2014Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
29013000 | USD |
CY2014Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
97520000 | USD |
CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39983437 | shares |
CY2014Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
39983437 | shares |
CY2014Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42046083 | shares |
CY2014Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42046083 | shares |
CY2013Q1 | us-gaap |
Licenses Revenue
LicensesRevenue
|
147000 | USD |
CY2013Q1 | us-gaap |
Revenues
Revenues
|
147000 | USD |
CY2013Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4522000 | USD |
CY2013Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
13533000 | USD |
CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18055000 | USD |
CY2013Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
52000 | USD |
CY2013Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-506000 | USD |
CY2013Q1 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
80000 | USD |
CY2013Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
89000 | USD |
CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18414000 | USD |
CY2014Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3656000 | USD |
CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
30875424 | shares |
CY2014Q1 | us-gaap |
Revenues
Revenues
|
9081000 | USD |
CY2014Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
22503000 | USD |
CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13422000 | USD |
CY2014Q1 | supn |
Increase Decrease In Deferred Product Revenue Net
IncreaseDecreaseInDeferredProductRevenueNet
|
4389000 | USD |
CY2014Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2121000 | USD |
CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15543000 | USD |
CY2014Q1 | supn |
Increase Decrease In Deferred Licensing Revenue
IncreaseDecreaseInDeferredLicensingRevenue
|
-67000 | USD |
CY2013Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17908000 | USD |
CY2013Q1 | us-gaap |
Interest Expense
InterestExpense
|
727000 | USD |
CY2014Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
8995000 | USD |
CY2014Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
494000 | USD |
CY2013Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-32000 | USD |
CY2013Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-32000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-134000 | USD |
CY2013Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
337000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1650000 | USD |
CY2013Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-18446000 | USD |
CY2014Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1000 | USD |
CY2014Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-15542000 | USD |
CY2014Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.  Organization and Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Supernus Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.  The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market.</font></p> </div> | |
CY2013Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
80000 | USD |
CY2013Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
32000 | USD |
CY2013Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
162000 | USD |
CY2013Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
83000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
8000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1961000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
238000 | USD |
CY2013Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1936000 | USD |
CY2013Q1 | us-gaap |
Repayments Of Secured Debt
RepaymentsOfSecuredDebt
|
2832000 | USD |
CY2013Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
125000 | USD |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1021000 | USD |
CY2013Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-21393000 | USD |
CY2013Q1 | us-gaap |
Interest Paid
InterestPaid
|
610000 | USD |
CY2014Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-20728000 | USD |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5000 | USD |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1629000 | USD |
CY2013Q1 | supn |
Increase Decrease In Deferred Product Revenue Net
IncreaseDecreaseInDeferredProductRevenueNet
|
3551000 | USD |
CY2013Q1 | supn |
Increase Decrease In Deferred Licensing Revenue
IncreaseDecreaseInDeferredLicensingRevenue
|
373000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
44000 | USD |
CY2013Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
15643000 | USD |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17223000 | USD |
CY2013Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
12866000 | USD |
CY2013Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
372000 | USD |
CY2014Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
1056000 | USD |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3149000 | USD |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19104000 | USD |
CY2013Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18909000 | USD |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32980000 | USD |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
40302000 | USD |
CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.60 | |
CY2014Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-1693000 | USD |
CY2014Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-576000 | USD |
CY2014Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
9406000 | USD |
CY2013Q4 | supn |
Allowance For Expected Prompt Pay Discounts
AllowanceForExpectedPromptPayDiscounts
|
100000 | USD |
CY2014Q1 | supn |
Allowance For Expected Prompt Pay Discounts
AllowanceForExpectedPromptPayDiscounts
|
100000 | USD |
CY2014Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
9096000 | USD |
CY2014Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
46615000 | USD |
CY2014Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
11662000 | USD |
CY2014Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
263000 | USD |
CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
6000 | USD |
CY2014Q1 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
1000 | USD |
CY2014Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
10418000 | USD |
CY2014Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
46615000 | USD |
CY2014Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
9725000 | USD |
CY2014Q1 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
636000 | USD |
CY2014Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2559000 | USD |
CY2014Q1 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
185000 | USD |
CY2014Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
40000000 | USD |